Loading...
XNAS
SMMT
Market cap18bUSD
May 13, Last price  
24.61USD
1D
-2.57%
1Q
25.75%
Jan 2017
187.50%
Name

Summit Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
34.35%
Rev. gr., 5y
165.43%
Revenues
0k
947,8922,028,2066,025,174266,639301,9451,207,4502,771,5832,865,2202,268,0782,268,07802,879,89235,979,78756,412,879811,370860,0001,809,000704,29500
Net income
-221m
L-64.01%
00000000000009,872,122-30,662,295-52,697,000-86,147,000-74,381,000-614,928,000-221,315,000
CFO
-142m
L+85.13%
0000000000015,175,68000-19,981,899-48,111,000-72,587,000-41,582,000-76,760,000-142,106,000
Earnings
Aug 04, 2025

Profile

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
URL
https://www.smmttx.com/
IPO date
Oct 14, 2004
Employees
76
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122019‑012018‑012017‑012016‑01
Income
Revenues
704
-61.07%
Cost of revenue
226,311
89,736
81,213
Unusual Expense (Income)
NOPBT
(226,311)
(89,736)
(80,509)
NOPBT Margin
Operating Taxes
(946)
(4,401)
Tax Rate
NOPAT
(226,311)
(88,790)
(76,108)
Net income
(221,315)
-64.01%
(614,928)
726.73%
(74,381)
-13.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
477,893
5,000
100,000
BB yield
-3.73%
-0.31%
-12.17%
Debt
Debt current
3,765
2,809
21,460
Long-term debt
10,671
109,389
501,756
Deferred revenue
Other long-term liabilities
1,630
1,562
1,429
Net debt
(397,913)
(74,044)
174,609
Cash flow
Cash from operating activities
(142,106)
(76,760)
(41,582)
CAPEX
(139)
(128)
(624)
Cash from investing activities
(205,341)
(587,774)
(624)
Cash from financing activities
381,227
86,513
620,244
FCF
(227,646)
201,011
(367,499)
Balance
Cash
412,349
186,242
348,607
Long term investments
Excess cash
412,349
186,242
348,572
Stockholders' equity
(1,209,482)
(988,689)
(378,113)
Invested Capital
1,607,078
1,174,042
1,024,959
ROIC
ROCE
EV
Common stock shares outstanding
718,542
619,646
193,336
Price
17.85
583.72%
2.61
-38.59%
4.25
57.99%
Market cap
12,822,380
692.84%
1,617,277
96.83%
821,678
231.16%
EV
12,424,467
1,543,233
996,287
EBITDA
(226,222)
(87,686)
(77,995)
EV/EBITDA
Interest
8,686
16,461
4,401
Interest/NOPBT